Corrigendum


Sara Valpione a,b, Matteo S. Carlino c,d, Johanna Mangana e, Meghan J. Mooradian f, Grant McArthur g, Dirk Schadendorfh, Axel Hauschild i, Alexander M. Menzies c,j, Ana Arancé k, Paolo A. Ascierto l, Anna Maria Di Giacomo m, Francesco de Rosa n, James Larkin o, John J. Park c,d, Simone M. Goldinger e, Ryan J. Sullivan f, Wen Xu g, Elisabeth Livingstone h, Michael Weichenthal i, Rajat Rai e, Lydia Gaba k, Georgina V. Long c,j, Paul Lorigan a,*

a The Christie NHS Foundation Trust, University of Manchester, Manchester, UK
b CRUK Manchester Institute, Manchester, UK
c Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia
d Westmead and Blacktown Hospitals, Westmead, Australia
e University Hospital of Zurich, Zurich, Switzerland
f Massachusetts General Hospital, Cancer Center, Boston, MA, USA

* Corresponding author: University of Manchester and Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK.
Fax: +44 (0) 161 446 3299.
E-mail address: paul.lorigan@christie.nhs.uk (P. Lorigan).

DOI of original article: https://doi.org/10.1016/j.ejca.2017.12.007.
The present study was partially presented at ASCO 2017 (abstract 9512).

The Authors regret that there was a typo in the percentage of response groups in the abstract and main text. The 3rd sentence is the abstract should read:

“The RR to rechallenge with BRAFi ± MEKi was 43.3%, complete response (CR) 2.6%, partial response (PR) 40.7%, stable disease (SD) 24.8% and progressive disease 31.9%, 3 missing.”

The 15th sentence is the abstract should read:

“The overall RR to BRAFi rechallenge was 43.3% for evaluable patients: CR in 3 patients (2.6%), PR in 46 (40.7%), SD in 28 (24.8%), PD in 36 (31.9%) and data missing in 3 patients.”

The authors would like to apologise for any inconvenience caused.